Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 • 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

June 17, 2022 • 00:37:25
Episode Cover

Life-Threatening Asthma

Approximately 2 million patients present each year to EDs in the United States for acute asthma exacerbations.  Of these, up to 50,000 may require...

Listen

Episode

June 07, 2024 • 00:22:24
Episode Cover

Cefepime vs. Piperacillin-Tazobactam for Infection?  The ACORN Trial

Timely and appropriate administration of empiric broad-spectrum antibiotics for adult patients with sepsis is critical.  Current guidelines recommend an antipseudomonal antibiotic for those at...

Listen

Episode 0

March 18, 2022 • 00:30:35
Episode Cover

The Critically Ill Patient with HHS

Hyperglycemic hyperosmolar syndrome (HHS) is a potentially life-threatening hyperglycemic emergency that has a mortality that can be 10 times as high compared with patients...

Listen